The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients

Pharmacogenomics

Volumn 12, Issue 8, 2011, Pages 1137-1146

  Van Schaik, Ron H N ^a   Kok, Marleen ^b   Sweep, Fred C J ^c   Van Vliet, Martin ^a   Van Fessem, Marianne ^a   Meijer Van Gelder, Marion E ^d   Seynaeve, Caroline ^d   Lindemans, Jan ^a   Wesseling, Jelle ^b   Van 'T Veer, Laura J ^b   Span, Paul N ^c   Van Laarhoven, Hanneke ^c   Sleijfer, Stefan ^d   Foekens, John A ^d   Linn, Sabine C ^b   Berns, Els M J ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

breast cancer; CYP2C19; pharmacogenetic; tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2D6; DNA; PROGESTERONE RECEPTOR; UNSPECIFIC MONOOXYGENASE;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYP2C19 2 GENE; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MARKER GENE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; BREAST TUMOR; ENZYMOLOGY; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; MENOPAUSE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHARMACOGENETICS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYTOCHROME P-450 CYP2D6; DATA INTERPRETATION, STATISTICAL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 80051761150     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.54     Document Type: Article

References (36)

1. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2(3), 205-213 (2003). (Pubitemid 37361665)
2. Ingle JN. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 112(Suppl. 3), 695-699 (2008). (Pubitemid 351186391)
3. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 13(2), 513-529 (1995).
4. Lonning PE, Lien EA, Lundgren S, Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin. Pharmacokinet. 22(5), 327-358 (1992).
5. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95(23), 1758-1764 (2003). (Pubitemid 38008898)
6. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 57(16), 3402-3406 (1997). (Pubitemid 27355484)
7. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53(2), 171-178 (1997). (Pubitemid 27013472)
8. Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 256(2), 859-868 (1981). (Pubitemid 11103040)
9. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42(1), 317-323 (1982). (Pubitemid 12207285)
10. Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res. Treat. 2(2), 123-138 (1982). (Pubitemid 13233530)
11. Johnson MD, Zuo H, Lee KH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85(2), 151-159 (2004). (Pubitemid 38987269)
12. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005).
13. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor a for degradation in breast cancer cells. Cancer Res. 69(5), 1722-1727 (2009).
14. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113-121 (2007). (Pubitemid 47555336)
15. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312-9318 (2005).
16. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009).
17. Brauch H, Murdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin. Chem. 55(10), 1770-1782 (2009).
18. Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin. Cancer Res. 15(1), 15-21 (2009).
19. Ruiter R, Bijl MJ, van Schaik RH et al. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 11(10), 1367-1375 (2010).
20. Holm C, Kok M, Michalides R et al. Phosphorylation of the oestrogen receptor a at serine 305 and prediction of tamoxifen resistance in breast cancer. J. Pathol. 217(3), 372-379 (2009).
21. Kok M, Linn SC, Van Laar RK et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 113(2), 275-283 (2009).
22. Span PN, Waanders E, Manders P et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J. Clin. Oncol. 22(4), 691-698 (2004). (Pubitemid 41095073)
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97(16), 1180-1184 (2005). (Pubitemid 41258223)
24. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310(3), 1062-1075 (2004). (Pubitemid 39108928)
25. Williams ML, Lennard MS, Martin IJ, Tucker GT. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis 15(12), 2733-2738 (1994).
26. Ogura K, Ishikawa Y, Kaku T et al. Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem. Pharmacol. 71(9), 1358-1369 (2006).
27. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J. Clin. Oncol. 10(2), 304-310 (1992).
28. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M. Acquired tamoxifen resistance. Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. Natl Cancer Inst. 83(20), 1477-1482 (1991).
29. Johnston SR, Haynes BP, Smith IE et al. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 342(8886-8887), 1521-1522 (1993). (Pubitemid 23362172)
30. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25(33), 5187-5193 (2007). (Pubitemid 350232249)
31. Justenhoven C, Hamann U, Pierl CB et al. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res. Treat. 115(2), 391-396 (2009).
32. Dunn BK, Greene MH, Kelley JM et al. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int. J. Mol. Epidemiol. Genet. 1(4), 332-349 (2010).
33. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes. formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30(8), 869-874 (2002). (Pubitemid 34815415)
34. Nishiyama T, Ogura K, Nakano H et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis-and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem. Pharmacol. 63(10), 1817-1830 (2002). (Pubitemid 34603446)
35. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res. 8(4), R50 (2006).
36. Coller JK, Krebsfaenger N, Klein K et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol. 54(2), 157-167 (2002). (Pubitemid 35024939)